کارگاه‌های آموزشی مرکز اطلاعات علمی

مقاله نویسی علوم انسانی

اصول تنظیم قراردادها

آموزش مهارت های کاربردی در تدوین و چاپ مقاله
Original Article

Relationship between gamma-glutamyl transferase and glucose intolerance in first degree relatives of type 2 diabetics patients

Sassan Haghighia, Massoud Aminib, Zahra Pournaghshbandc,
Peyvand Ain, Silva Hovsepiana

Abstract

BACKGROUND: Considering that serum gamma-glutamyl transferase (GGT) activity could reflect several different processes relevant to diabetes pathogenesis and the increasing rate of type 2 diabetes worldwide, the aim of this study was to assess the association between serum GGT concentrations and glucose intolerance, in the first-degree relatives (FDR) of type 2 diabetic patients.

METHODS: In this descriptive study, 30-80 years old, non diabetic FDRs of type 2 diabetic patients were studied. Serum GGT was measured by enzymatic photometry method in all studied population. The relationship between GGT and glucose intolerance status (normal, prediabetic and diabetic) was evaluated.

RESULTS: During this study 551 non-diabetic FDRs of type 2 diabetic patients were studied. Mean of GGT was 25.3 ± 12.1 IU/L. According to glucose tolerance test, 153 were normal and 217 and 181 were diabetic and prediabetic respectively. Mean of GGT in normal, prediabetic and diabetic patients was 23.5 ± 15.9 IU/L, 29.1 ± 28.1 IU/L and 30.9 ± 24.8 IU/L respectively (p = 0.000). The proportion of prediabetic and diabetic patients was higher in higher quartile of GGT and there was a significant correlation between GGT and BMI, HbA1c, FPG, cholesterol, LDL-C, and triglyceride (p < 0.05). There was a significant relation between GGT and area under the curve (AUC) of oral glucose tolerance test (p = 0.00).

CONCLUSIONS: Measurement of GGT in FDRs of type 2 diabetic patients may be useful in assessing the risk of diabetes; those with chronically high levels of GGT should be considered as high risk group for diabetes.

KEYWORDS: Gamma-Glutamyltransferase, Glucose Intolerance, Diabetes Mellitus, Type 2.

Serum gamma-glutamyl transferase (GGT) is an ectoplasmic enzyme responsible for the extracellular catabolism of glutathione, which is synthesized in epithelial cells of the intrahepatic duct. It distributed in different cells with various secretory or absorptive activities. GGT has an important role in glutathione homeostasis by initiating the breakdown of extracellular glutathione and turnover of vascular glutathione. Considering the antioxidant activity of glutathione, increased level of GGT may be linked to greater oxidative stress. Increased oxidative stress has been implicated in insulin resistance by promoting ß-cell dysfunction and reducing insulin action. Therefore, serum GGT activity could reflect several different processes relevant to diabetes pathogenesis.

Many epidemiological studies, have demonstrated high rates of elevated GGT levels among diabetic patients over past 40 years. The association between serum GGT and poor glycemic state was also documented in the 1980s. Recent prospective studies, have indi-
cated that baseline serum GGT activity predicts occurrence of future diabetes, stroke and cardiovascular diseases\textsuperscript{8,19} and within reference interval, it strongly predicted incident type 2 diabetes.\textsuperscript{10,13–18} However, not all studies support this assumption.\textsuperscript{20}

In a recent study, among general population, in Tehran, Tohidi et al have investigated the association of GGT with incident type 2 diabetes. According to their findings, GGT was not independently associated with diabetes, but after adjustments for family history, anthropometric factors and blood pressure, it had relationship with type 2 diabetes.\textsuperscript{21}

Considering the increasing rate of type 2 diabetes worldwide, in all ages, sexes, and race/ethnic groups,\textsuperscript{22} we designed this study to investigate the association between serum GGT concentration and glucose intolerance, in the first-degree relatives (FDR) of type 2 diabetic patients. However, no studies have been performed to date on these populations.

**Methods**

In this cohort study, non diabetic first-degree relatives of type 2 diabetic patients who were 30-80 years old and referred to Endocrine and Metabolic Research Center during Diabetes Prevention Project (DPP) study were enrolled (1893 FDRs of type 2 diabetic patients). For recruiting samples, we asked first-degree relatives of type 2 diabetic patients aged 30-80 years old to participate in the study by announcing through mass media. Informed consent was obtained from all studied subjects. Characteristics of studied subjects (demographic, familial history, past medical history …) were obtained using standard questionnaire.

The exclusion criteria were having a history of thyroid, renal, or hepatic disease, known diabetes, myocardial infarction, acute or chronic inflammatory disease or taking any medications.

**Physical Examinations**

All studied subjects were examined by physicians. Anthropometric measurements were performed by trained nurses. Height and weight was measured in standing position, with light clothing and bare foot using Seca measuring device.

**Laboratory Measurements**

In order to perform oral glucose tolerance test (OGTT), participants recommended using unrestricted diet with more than 150 g of carbohydrate daily and doing usual physical activities at least 3 days before laboratory tests. They recommended to fasting at least 10 hours before lab tests and not using any drug that may affect the metabolism of carbohydrate. After an overnight fasting, a 75 g OGTT was performed. Plasma glucose was measured using an enzymatic glucose oxidase technique using ChemEnzyme kit (Tehran-Iran). Plasma lipids including cholesterol, HDL-C and triglyceride (TG) were measured using enzymatic method by Liasys auto-analyzer (Italy). Gamma-glutamyl transferase (GGT) was analyzed by enzymatic photometry method using ParsAzmoon kit (Tehran-Iran).

Inter-assay coefficients of variations (CVs) were 1.25 for TG, 1.2 for cholesterol, 1.25% for glucose and 2.5% for GGT. The corresponding intra-assay CVs were 1.97, 1.6, 2.2 and 1.5 respectively.

HbA1c was measured by ion exchange chromatography with D55 set. LDL cholesterol was calculated using Friedwald formula.\textsuperscript{23}

Glucose intolerance in studied subjects was classified as below based on 2003 ADA criteria.\textsuperscript{24}

- **Diabetic:** FPG > 125 mg/dl (6.9 mmol/l) or 2h-PG > 199 mg/dl (11 mmol/l)
- **IFG:** 100 mg/dl (5.6 mmol/l) ≤ FPG ≤ 125 mg/dl (6.9 mmol/l) and 2h-PG < 140 mg/dl (7.8 mmol/l)
- **IGT:** FPG ≤ 100 mg/dl (5.6 mmol/l) and 140 mg/dl (7.8 mmol/l) ≤ 2h-PG ≤ 199 mg/dl (11 mmol/l)
- **Normal glucose tolerance (NGT):** FPG < 100 mg/dl (5.6 mmol/l) and 2h-PG < 140 mg/dl (7.8 mmol/l)

Patients with IFG and IGT considered as prediabetic.
Table 1. Baseline characteristics of first-degree relatives of type 2 diabetic patients (n = 551)

|                          | Mean ± SD        | Median (range) |
|--------------------------|------------------|----------------|
| Age (years)              | 49.1 ± 10.1      | 48 (30-80)     |
| BMI (kg/m²)              | 28.9 ± 4.6       | 28.5 (17.2-46.4) |
| FPG (mg/dl)              | 113.8 ± 43.2     | 109 (69-449)   |
| HbA1c (%)                | 6.5 ± 1.8        | 5.6 (4-12.5)   |
| Cholesterol (mg/dl)      | 96.9 ± 38.5      | 192 (116-385)  |
| HDL-C (mg/dl)            | 48.1 ± 12.9      | 47 (22-90)     |
| LDL-C (mg/dl)            | 116.1 ± 31.6     | 113.6 (34.8-279.2) |
| Triglyceride (mg/dl)     | 162.5 ± 88.5     | 140 (54-845)   |
| GGT* (U/L)               | 25.3 ± 12.1      | 21.9 (7.6-73.3) |

* gamma-glutamyltransferase

Statistical Analysis
Statistical analysis was performed using SPSS software version 13. Log transformation was used in order to reduce skewness. Otherwise, for variables which were not normally distributed, median was presented. For all other variables with normal distribution, data were presented as mean ± SD.

Mean and/or median of studied variables, between groups were compared using ANOVA, Kruskal-Wallis, Wilcoxon test (when appropriate) and Post hoc tests.

P values < 0.05 were considered statistically significant. We analyzed serum GGT levels as quartiles: less than 16.5 U/L, 16.5-21.9 U/L, 22-30.5 U/L, and more than 30.5 U/L.

To compare the prognostic abilities of GGT on glucose tolerance, we plotted glucose intolerance status against the quartiles of GGT.

Area under the receiver operating characteristic curve (AUC) of the logistic regression model was used to determine the cutoff of GGT as a predictive value for type 2 diabetes.

Results
551 non-diabetic first-degree relatives of type 2 diabetic patients aged 30-80 years old were studied. Baseline characteristics of all studied population are presented in table 1. Mean or median of studied variables in all studied population according to the GGT quartiles is presented in table 2.

From the studied population, 167 were men. Mean of GGT was 31.1 ± 13.2 and 22.7 ± 10.7 in men and women respectively (p < 0.001).

According to the ADA criteria, 153 out of 551 participants were normal and 217 and 181 were diabetic and prediabetic, respectively. Mean of GGT in normal, prediabetic and diabetic patients was 23.5 ± 15.9, 29.1 ± 28.1 and 30.9 ± 24.8 respectively (p < 0.001).

The proportion of normal, prediabetic and diabetic patients according to the quartiles of GGT is presented in figure 1.

The relation between GGT and area under the curve (AUC) of oral glucose tolerance test is presented in figure 2.

According to the results of GGT area under the receiver operating characteristic curve (AUC) of the logistic regression models, cutoff of GGT as a predictive value for type 2 diabetes was 14 U/L.

Table 2. Mean or median of studied variables in first-degree relatives of type 2 diabetic patients according to the gamma-glutamyl transferase quartiles (n = 551)

|                | Q1 (< 16.5) | Q2 (16.5-21.9) | Q3 (22-30.5) | Q4 (> 30.5) | P value |
|----------------|-------------|----------------|--------------|-------------|---------|
| Age (years)    | 46.9 ± 10.2 | 47.5 ± 9.3     | 51.4 ± 10.7  | 50.6 ± 9.8  | p < 0.05 |
| BMI (kg/m²)    | 28.0 ± 4.8  | 28.9 ± 4.5     | 28.8 ± 4.0   | 30.0 ± 4.8  | p < 0.05 |
| FPG (mg/dl)    | 100 (61-449)| 107.5 (78-376)| 116 (78-386) | 125 (68-425)| p < 0.05 |
| HbA1c (%)      | 5.3 (4-10)  | 5.6 (4.1-11.7) | 5.6 (4.4-11.6)| 5.9 (4.1-12.5)| p < 0.05 |
| Cholesterol (mg/dl) | 187.7 ± 30.8| 193.9 ± 34.1  | 197.5 ± 42.3 | 208.8 ± 47.8| p < 0.05 |
| HDL-C (mg/dl)  | 51.3 ± 13.4 | 46.8 ± 12.6    | 47.1 ± 12.5  | 47.2 ± 12.9 | p < 0.05 |
| LDL-C (mg/dl)  | 111.9 ± 27.0| 116.8 ± 30.0   | 114.5 ± 33.2 | 121.3 ± 35.5| 0.3     |
| Triglyceride (mg/dl)| 123.3 ± 65.4| 152.3 ± 65.4  | 181.8 ± 107.7| 193.2 ± 91.8| p < 0.05 |
There was a significant positive correlation between GGT and BMI, HbA1c, FPG, cholesterol, LDL-C, Triglyceride; but there was no relation with HDL-C. Age and sex were considered as control variables.
Discussion
Although the association between serum levels of GGT and type 2 diabetes risk has been documented in several previous studies, to the best of our knowledge, this study was the first report to investigate this relationship in the FDRs of diabetic patients. The findings of our study have demonstrated that there was similar association between GGT and glucose intolerance in FDRs of diabetic patients and there was a relation between serum GGT and risk for development of IFG or type 2 diabetes. A GGT level of 14 U/L considered as cutoff point for predicting diabetes in FDRs of diabetic patients.

Mean of GGT in current study in all the studied population was 25.3 U/L; however, it was higher in prediabetic and diabetic FDRs.

In a population based study in Tehran, Tohidi et al have reported that median of GGT in subjects who did and did not develop diabetes after 3.5 years of follow-up was 16.9 U/L and 21.3 U/L, respectively. Results of current study were in line with the study of Tohidi et al. Median of GGT in FDRs was similar to those subjects who developed diabetes after 3.5 years of follow-up in Tehran. This may be due to our studied population who were the first degree relatives of type 2 diabetes who are at higher risk for diabetes development.

The mean of GGT in Iranian healthy volunteer blood donors men was reported to be 20.52 U/L by Khedmat et al. Mean of GGT in this study was higher in men than in women, which was similar to the Hisayama study.

These different results may be due to different methods of GGT measurements or differences in studied population. However, we could not ignore the importance of genetic and environmental sources of variations in GGT.

Several studies have demonstrated the association between serum GGT level and diabetes. Some of them have indicated that GGT is a more powerful predictor of incident diabetes than other liver enzymes. The results of these observations are different; our results are consistent with most but not all previous studies that evaluate the above mentioned association.

In the study of Khedmat et al in Iran, the prevalence of diabetes and also the presence of diabetes family history were not different regarding GGT quartile. Whereas, Tohidi et al have indicated that GGT was not associated with incident of type 2 diabetes, independent of classic risk factors; however, it predicted diabetes after adjustment for family history of diabetic patients as well as some factors including, body mass index, waist circumference, waist to hip ratio, systolic blood pressure and diastolic blood pressure. It lost its association with diabetes after further adjustment for other metabolic factors such as FPG, 2 hour postprandial glucose, triglyceride and HDL-C.

Nakanishi et al investigated the association between serum GGT and risk of type 2 diabetes. The results of their investigation indicated that serum GGT may be an important predictor for developing type 2 diabetes mellitus and in accordance to our results, they concluded that the relative risk for impaired fasting glucose and type 2 diabetes increased as serum GGT increased.

Recently, Sabanayagam et al have studied the association between serum GGT and diabetes mellitus in a nationally representative sample of US adults participating in the National Health and Nutrition Examination Survey (NHANES) (1999-2002), among 7,976 adults older than 20 years old; according to their results, serum GGT levels were found to be positively associated with diabetes mellitus.

Kim et al in their study, in Korea, have shown that, the odds ratio of developing type 2 diabetes increased significantly with increasing GGT levels. In multiple logistic regression models adjusted for different variables, the highest quartile of GGT remained significantly associated with type 2 diabetes. They concluded that, increased serum GGT is independent and also additive risk factor for the development of diabetes in subjects without fatty liver or hepatic dysfunction.
Doi et al in Japan, have studied the relationship between liver enzymes and the development of diabetes in a general Japanese population. Their findings suggest that serum GGT concentration consider as a strong predictor of diabetes in the general population, independent of other known risk factors.26

There was a significant correlation between studied variables in our study and GGT, especially in higher quartile of GGT. The findings were in line with the results of Kim et al study.28

The limitations of the current study are that, the study was a cross-sectional study which limits making causal inferences in the association between serum GGT and glucose intolerance. In addition, GGT data were based on a single measurement which consequently limits the precision of the elevated GGT estimates and finally it seems that our results would be more conclusive if the sample size was larger.

Conclusions
Taken together, in spite of these limitations, the findings of this study could have practical and clinical implications in management of FDRs of diabetic patient. Measurement of GGT in this population may be useful in assessing the risk of type 2 diabetes and FDRs with chronically high levels of GGT (> 14) should be considered as high risk group for diabetes.

Conflict of Interests
Authors have no conflict of interests.

Authors’ Contributions
All authors have contributed in designing of the study. ZP collected the data. SaH, SiH and PA did the analysis and interpretation and assisted in preparation of the manuscript. MA served as a supervisor. All authors have read and approved the content of the manuscript.

References
1. Whitfield JB. Gamma glutamyl transferase. Crit Rev Clin Lab Sci 2001; 38(4): 263-355.
2. Lieberman MW, Barrios R, Carter BZ, Habib GM, Lebovitz RM, Rajagopalan S, et al. gamma-Glutamyl transpeptidase. What does the organization and expression of a multipromoter gene tell us about its functions? Am J Pathol 1995; 147(5): 1175-85.
3. Lee DH, Blomhoff R, Jacobs DR Jr. Is serum gamma glutamytransferase a marker of oxidative stress? Free Radic Res 2004; 38(6): 535-9.
4. Lee DH, Ha MJ, Kam S, Chun B, Lee J, Song K, et al. A strong secular trend in serum gamma-glutamyltransferase from 1996 to 2003 among South Korean men. Am J Epidemiol 2006; 163(1): 57-65.
5. Blaha M, Elasy TA. Clinical use of the metabolic syndrome: why the confusion? Clin Diabetes 2006; 24(3): 125-31.
6. Evans JL, Goldfine ID, Maddux BA, Grodsky GM. Are oxidative stress-activated signaling pathways mediators of insulin resistance and beta-cell dysfunction? Diabetes 2003; 52(1): 1-8.
7. Trell E, Kristenson H, Peterson B, Fex G, Henningsen NC, Berntorp K, et al. Two-hour glucose and insulin responses after a standardized oral glucose load in relation to serum gamma-glutamyl transferase and alcohol consumption. Acta Diabetol Lat 1981; 18(4): 311-7.
8. Wannamethee G, Ebrahim S, Shaper AG. Gamma-glutamyltransferase: determinants and association with mortality from ischemic heart disease and all causes. Am J Epidemiol 1995; 142(7): 699-708.
9. Brenner H, Rothenbacher D, Arndt V, Schuberth S, Fraisse E, Fliedner TM. Distribution, determinants, and prognostic value of gamma-glutamyltransferase for all-cause mortality in a cohort of construction workers from southern Germany. Prev Med 1997; 26(3): 305-10.
10. Perry IJ, Wannamethee SG, Shaper AG. Prospective study of serum gamma-glutamyltransferase and risk of NIDDM. Diabetes Care 1998; 21(5): 732-7.
11. Miuura K, Nakagawa H, Nakamura H, Tabata M, Nagase H, Yoshida M, et al. Serum gamma-glutamyl transferase level in predicting hypertension among male drinkers. J Hum Hypertens 1994; 8(6): 445-9.
12. Jousilahti P, Rastenyte D, Tuomilehto J. Serum gamma-glutamyl transferase, self-reported alcohol drinking, and the risk of stroke. Stroke 2000; 31(8): 1851-5.
13. Lee DH, Ha MH, Kim JH, Christiani DC, Gross MD, Steffes M, et al. Gamma-glutamyl transferase and diabetes—a 4 year follow-up study. Diabetologia 2003; 46(3): 359-64.
14. Lee DH, Jacobs DR Jr, Gross M, Kiefte CI, Roseman J, Lewis CE, et al. Gamma glutamyltransferase is a predictor of incident diabetes and hypertension: the Coronary Artery Risk Development in Young Adults (CARDIA) Study. Clin Chem 2003; 49(8): 1358-66.
15. Lee DH, Silventoinen K, Jacobs DR Jr, Jousilahti P, Tuomilehto J. Gamma-glutamyltransferase, obesity, and the risk of type 2 diabetes: observational cohort study among 20,158 middle-aged men and women. J Clin Endocrinol Metab 2004; 89(11): 5410-4.
16. André P, Balkau B, Born C, Charles MA, Eschwège E, The Desir Study Group. Three-year increase of gamma-glutamyltransferase level and development of type 2 diabetes in middle-aged men and women: the D.E.S.I.R. cohort. Diabetologia 2006; 49(11): 2599-603.
17. Nannipieri M, Gonzales C, Baldi S, Posadas R, Williams K, Haffner SM, et al. Liver enzymes, the metabolic syndrome, and incident diabetes: the Mexico City diabetes study. Diabetes Care 2005; 28(7): 1757-62.
18. Meisinger C, Löwel H, Heier M, Schneider A, Thorand B; KORA Study Group. Serum gamma-glutamyltransferase and risk of type 2 diabetes mellitus in men and women from the general population. J Intern Med 2005; 258(6): 357-365.
19. Ruttmann E, Brant RJ, Concine H, Diem G, Rapp K, Ulmer H; Vorarlberg Health Monitoring and Promotion Program Study Group. Gamma-glutamyltransferase as a risk factor for cardiovascular disease mortality: an epidemiological investigation in a cohort of 163,944 Austrian adults. Circulation 2005; 112(14): 2130-7.
20. Vozarova B, Stefan N, Lindsay RS, Saremi A, Pratley RE, Bogardus C, et al. High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes. Diabetes 2002; 51(6): 1889-95.
21. Tohidi M, Harati H, Hadaegh F, Mehrabi Y, Azizi F. Association of liver enzymes with incident type 2 diabetes: a nested case control study in an Iranian population. BMC Endocr Disord 2008; 8: 5.
22. King, H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998; 21(9): 1414-31.
23. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus, Diabetes Care 2003; 26(Suppl 1): S5-20.
24. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18(6): 499-502.
25. Khedmat H, Fallahian F, Abolghasemi H, Hajibeigi B, Atarchi Z, Alaeddini F, et al. Serum gamma-glutamyltransferase, alanine aminotransferase, and aspartate aminotransferase activity in Iranian healthy blood donor men. World J Gastroenterol 2007; 13(6): 889-94.
26. Doi Y, Kuro M, Yonemoto K, Ninomiya T, Iwase M, Tanizaki Y, et al. Liver enzymes as a predictor for incident diabetes in a Japanese population: the Hisayama study. Obesity (Silver Spring) 2007; 15(7): 1841-50.
27. Whitfield JB, Zhu G, Nestler JE, Heath AC, Martin NG. Genetic covariation between serum gamma-glutamyltransferase activity and cardiovascular risk factors. Clin Chem 2002; 48(9): 1426-31.
28. Kim CH, Park JY, Lee KU, Kim JH, Kim HK. Association of serum gamma-glutamyltransferase and alanine aminotransferase activities with risk of type 2 diabetes mellitus independent of fatty liver. Diabetes Metab Res Rev 2009; 25(1): 649.
29. Nakashishi N, Nishina K, Li W, Sato M, Suzuki K, Tatara K. Serum gamma-glutamyltransferase and development of impaired fasting glucose or type 2 diabetes in middle-aged Japanese men. J Intern Med 2003; 254(3): 287-95.
30. Sabanayagam C, Shankar A, Li J, Pollard C, Ducatman A. Serum gamma-glutamyl transferase level and diabetes mellitus among US adults. Eur J Epidemiol 2009; 24(7): 369-73.
کارگاه‌های آموزشی مرکز اطلاعات علمی

مقاله‌نویسی علوم انسانی

اصول تنظیم قراردادها

آموزش مهارت‌های کاربردی در تدوین و چاپ مقاله